Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-TechneTECH +0.06%88 EV-to-OCF is 38.39 as of Aug. 04, 2026, which is 7% below its 10-year median of 41.48. GuruFocus rates TECH with a GF Score™ of 88/100 and a GF Value™ of $72.80 (Fairly Valued). The stock has 8 warning signs investors should review. Among 1,411 Biotechnology companies, Bio-Techne ranks worse than 94.05% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Bio-Techne's Enterprise Value is $11,321 Mil.
Bio-Techne's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $295 Mil. Therefore, Bio-Techne's EV-to-OCF for today is 38.39.
The historical rank and industry rank for Bio-Techne's EV-to-OCF or its related term are showing as below:
TECH'
s EV-to-OCF Range Over the Past 10 Years
Min: 23.39 Med: 41.48 Max: 65.77
Current: 38.39
During the past 13 years, the highest EV-to-OCF of Bio-Techne was 65.77. The lowest was 23.39. And the median was 41.48.
TECH's EV-to-OCF is ranked worse than 94.05% of 1411
companies
in the Biotechnology industry
Industry Median: -3.32
vs TECH: 38.39
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio-Techne's share price for today is $72.14.
Bio-Techne's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bio-Techne EV-to-OCF Related Terms
Bio-Techne EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Bio-Techne's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Techne's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Bio-Techne's EV-to-OCF falls into.
Bio-Techne's current Enterprise Value is $11,321 Mil.
Bio-Techne's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $295 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (TECH) has a EV-to-OCF of 38.39 as of Aug. 04, 2026. This is near median its historical median of 41.48. Over the past decade, Bio-Techne's EV-to-OCF has ranged from 23.39 to 65.77. According to the industry distribution chart, Bio-Techne ranks #1327 out of 1411 companies in the Biotechnology industry, placing it in the top 94%.
Is Bio-Techne's EV-to-OCF too high?
Bio-Techne's current EV-to-OCF of 38.39 is near median its 10-year median of 41.48. Over the past 10 years, this metric has ranged from a low of 23.39 to a high of 65.77. Based on the distribution chart, Bio-Techne ranks #1327 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bio-Techne has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's EV-to-OCF compare to CYTK and SMMT?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #1327 out of 1411 companies for EV-to-OCF. This places Bio-Techne in the lower half of its industry. Historically, Bio-Techne's own EV-to-OCF has ranged from 23.39 to 65.77 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Bio-Techne's current EV-to-OCF is 38.39, which is near median its own 10-year median of 41.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (TECH) is currently considered Fairly Valued. The stock's GF Value™ is $72.80, compared to a current price of $72.14 — trading 0.9% below its estimated fair value. The current EV-to-OCF is 38.39, which is near median its 10-year median of 41.48. Bio-Techne's overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Bio-Techne (TECH), the current EV-to-OCF is 38.39 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of $72.14 is trading 0.9% below its estimated GF Value™ of $72.80.
GuruFocus considers Bio-Techne to be Fairly Valued.
Key valuation signals for TECH:
EV-to-OCF: 38.39 (near median its 10-year median of 41.48)
GF Value™: $72.80 vs. price of $72.14 (0.9% below fair value)
No single metric tells the full story. See the TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
88GF Score
Get the complete analysis for TECH
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TECH has been successfully added to your 
